| Status: Medicine does not meet criteria for AWMSG assessment | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA903: Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer |
|
Medicine details |
|
| Medicine name | darolutamide (Nubeqa®) |
| Formulation | 300mg film-coated tablet |
| Reference number | 3330 |
| Indication | Treatment of patients with metastatic, hormone-sensitive prostate cancer |
| Company | Bayer Healthcare Pharmaceuticals |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 01/12/2022 |
| NICE guidance | |